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John R PetrieAbstract
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore
managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective
recent additions to the glucose-lowering treatment armamentarium for type 2 diabetes mellitus (T2D),
understanding their CV safety profiles is of great importance. Glucagon-like peptide-1 (GLP-1) receptor agonists
have been associated with beneficial effects on CV risk factors, including weight, blood pressure and lipid profiles.
Encouragingly, mechanistic studies in preclinical models and in patients with acute coronary syndrome suggest a
potential cardioprotective effect of native GLP-1 or GLP-1 receptor agonists following ischaemia. Moreover,
meta-analyses of phase 3 development programme data indicate no increased risk of major adverse cardiovascular
events (MACE) with incretin-based therapies. Large randomized controlled trials designed to evaluate long-term CV
outcomes with incretin-based therapies in individuals with T2D are now in progress, with the first two reporting as
this article went to press.
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Cardiovascular disease (CVD) is a leading cause of mor-
bidity and mortality in people with diabetes, and is re-
sponsible for half of all deaths of these individuals [1].
Although there are trends toward a fall in this excess
mortality risk (perhaps due to earlier detection of type 2
diabetes (T2D) coupled with improvements in care),
people with T2D have an elevated risk of CVD com-
pared with those without T2D and a poorer prognosis
following an adverse CV event [2,3]. The excess CV risk
associated with T2D may arise from a complex interplay
of several factors, including chronic hyperglycaemia,
hypertension, dyslipidaemia, and obesity [4].
Management of CVD risk factors is therefore of vital
importance in T2D care. Improving glycaemic control
has provided only limited success in reducing the
macrovascular complications associated with T2D [5,6],
and so focus has inexorably shifted towards other CV
risk factors (including hypertension, dyslipidaemia, and
obesity) that contribute to CV morbidity and mortality.
More recently, the prevailing assumption that glucose-Correspondence: john.petrie@glasgow.ac.uk
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reproduction in any medium, provided the orlowering is inextricably linked with outcome benefit
has been challenged [7,8] with the suspension of the
European marketing authorisation for rosiglitazone in
2010, and restriction of its use in the U.S., following con-
cerns of an increased risk of CV disorders, including myo-
cardial infarction (MI), heart failure [9], and stroke [10].
Determining the optimal therapy regimen for individ-
uals with T2D therefore requires careful consideration,
and evidence regarding long-term CV safety of glucose-
lowering therapies is required to inform better clinical
decision-making. In 2008, the U.S. Food and Drug Ad-
ministration (FDA) responded to this need by issuing
guidelines that mandate a thorough assessment of CV
risk in glucose-lowering drug development programmes
[11]. The incretin-based therapies are the first drug
classes to emerge within this environment of height-
ened regulatory attention. Clinical studies of incretin-
based therapies have demonstrated improved glycaemic
control with a low risk of hypoglycaemia and no weight
gain, or in the case of glucagon-like peptide-1 (GLP-1)
receptor agonists, weight loss [12,13]. These effects,
alongside others (summarised in Figure 1) are attractive
therapeutic properties in the management of T2D, and
signal potential CV benefit. Long-term CV outcomesis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Mechanisms underlying the putative cardiovascular effects of incretin-based therapies. ANP, atrial natriuretic peptide,
IR, ischaemia-reperfusion.
Petrie Cardiovascular Diabetology 2013, 12:130 Page 2 of 12
http://www.cardiab.com/content/12/1/130trials are currently underway for many of the incretin-
based therapies (Table 1) [14-24]. This review provides
background information on the endogenous incretin
system and incretin-based therapies, and examines the
available data regarding the effects on CV risk markers
and CV safety with incretin-based therapies.
Evidence acquisition
A literature search of established sources, including con-
gress abstracts, was performed to identify recent publi-
cations dealing with the topic for review. Relevant
articles were selected for review and discussion in light
of the author’s knowledge of the field and clinical judge-
ment. The European label for lixisenatide [25] was con-
sulted for additional information. The official clinical
trials registry at www.clinicaltrials.gov was also searched
to identify long-term CV outcomes clinical trials with
incretin-based therapies in individuals with T2D.
The incretin system and incretin-based therapies
Following nutrient intake, two major incretin hormones,
GLP-1 and glucose-dependent insulinotropic polypep-
tide (GIP), are secreted from the gastrointestinal tract
into the circulation [26]. It is now recognised that GLP-
1 and GIP are responsible for 50–70% of total insulin se-
cretion after oral glucose intake in healthy individuals
[26], augmenting insulin release in a glucose-dependent
manner, and leading to reductions in average blood glu-
cose levels. GLP-1 exerts an additional glucose-lowering
effect through actions at pancreatic alpha cells which re-
sult in an inhibition of glucagon secretion [26]. There is
evidence to suggest that the incretin system is function-
ally impaired in people with T2D, although this is not
universally observed [27-31]. This impairment may con-
tribute to the characteristic postprandial hyperglycaemia
observed in affected individuals [27]. Native GLP-1 has
been shown to reduce hyperglycaemia in T2D; however,
as GLP-1 is rapidly (within 2–3 minutes) degraded bythe enzyme dipeptidyl peptidase-4 (DPP-4), continuous
GLP-1 infusion would be required to maintain optimal
glycaemic control [32]. Therefore, incretin-based therapies
have been developed either to raise endogenous levels of
incretin hormones (DPP-4 agonists) or to mimic GLP-1
effects (GLP-1 receptor agonists) over more extended
timeframes.
Pharmacological inhibition of the DPP-4 enzyme with
DPP-4 inhibitors increases plasma incretin hormone levels.
Several different oral DPP-4 inhibitors are clinically avail-
able, including sitagliptin, saxagliptin, linagliptin, alogliptin,
vildagliptin (in the EU and Australia), teneligliptin and
analagliptin (both available only in Japan) and gemigliptin
(available only in Korea). Subcutaneous injection of GLP-1
receptor agonists mimics the effects of native GLP-1
through stimulation of the Gs-protein coupled GLP-1 re-
ceptor. Two GLP-1 receptor agonists are currently widely
available: liraglutide (a GLP-1 analogue with 97% homology
to native human GLP-1) and exenatide (53% homology to
native human GLP-1). Exenatide was introduced to the
market in 2007, having been developed from the peptide
exendin-4 in the venom of the Gila monster, and is admin-
istered twice daily (BID). A major advantage of liraglutide
when introduced in 2009 was its once daily administration.
An extended release once-weekly formulation of exenatide
(also known as exenatide long-acting release [LAR]) is also
available in both the European Union [33] and in the U.S.
[34]. Lixisenatide, a novel GLP-1 receptor agonist, was re-
cently launched in several regions, including the European
Union [25], and a number of GLP-1 receptor agonists are
currently in clinical development, including albiglutide.
Cardiovascular effects of native GLP-1
The effects of native GLP-1 on contractility, heart rate
and/or blood pressure have been investigated [35-37],
but are not well-established. Differing effects of native
GLP-1 on these parameters have been observed, present-
ing a complex picture. These varying effects may arise
Table 1 Randomised clinical trials investigating long-term cardiovascular outcomes with incretin-based therapies in people with T2D
Title Trialacronym Intervention Enrolment
Study
duration Primary outcome measure
Date initiated
(month/year)
Primary completion date
(month/year)
GLP-1 receptor agonists
A Randomized Double Blind, Placebo-controlled
Clinical Trial to Assess the Effects of Taspoglutide
(RO5073031) on Cardiovascular Outcomes in Subjects
with Inadequately Controlled Type 2 Diabetes and
Established Cardiovascular Disease/NCT01018173
T-EMERGE-8
Taspoglutide
20 mg once
weekly
2118
Event-
driven
timeframe,
≤2 years
anticipated
Time to a CV composite endpoint
(CV death, acute MI, stroke or
hospitalisation for unstable angina)
01/2010
Trial suspended 09/2010 due to
high discontinuation rates
(gastrointestinal intolerability and
serious hypersensitivity reactions)
Liraglutide Effect and Action in Diabetes: Evaluation
of Cardiovascular Outcome Results - A Long Term
Evaluation/NCT01179048
LEADER
Liraglutide
1.8 mg OD
9340 ≤60 months
Time from randomisation to first
occurrence of CV death, non-fatal
MI or non-fatal stroke
08/2010 01/2016
Exenatide Study of Cardiovascular Event Lowering
Trial: A Trial To Evaluate Cardiovascular Outcomes
After Treatment With Exenatide Once Weekly In
Patients With Type 2 Diabetes Mellitus/NCT01144338
EXSCEL
Exenatide
2 mg once
weekly
9500 5.5 years
Time to first confirmed CV event in
a composite CV endpoint
06/2010 03/2017
Evaluation of Cardiovascular Outcomes in Patients
With Type 2 Diabetes After Acute Coronary
Syndrome During Treatment With AVE0010
(Lixisenatide)/NCT01147250
ELIXA
Lixisenatide
20 μg OD 6000 203 weeks Time to first confirmed CV event 06/2010 09/2014
Researching Cardiovascular Events With a Weekly
Incretin in Diabetes/NCT01394952 REWIND
Dulaglutide
1.5 mg once
weekly
9622 ≤6.5 years
Time from randomisation to first
occurrence of CV death, non-fatal
MI or non-fatal stroke
07/2011 04/2019
Trial to Evaluate Cardiovascular and Other Long-term
Outcomes With Semaglutide in Subjects With Type 2
Diabetes/ NCT01720446
SUSTAIN 6
Semaglutide
0.5 mg or
1.0 mg once
weekly
3260 ≤148 weeks
Time from randomisation to first
occurrence of CV death, non-fatal
MI or non-fatal stroke
02/2013 01/2016
DPP-4 inhibitors
Sitagliptin Cardiovascular Outcome Study
(0431–082 AM1)/NCT00790205
TECOS
Sitagliptin
phosphate
50 mg or
100 mg OD
14000 ≤5 years Time to first confirmed CV event 12/2008 12/2014
Does Saxagliptin Reduce the Risk of Cardiovascular
Events When Used Alone or Added to Other
Diabetes Medications/NCT01107886
SAVOR-
TIMI 53
Saxagliptin
2.5 mg or
5 mg OD
16492 ≤2.1 years
Time from randomisation to first
occurrence of CV death, non-fatal
MI or non-fatal stroke
05/2010 Completed 05/2013
Cardiovascular Outcome Study of Linagliptin Versus
Glimepiride in Patients With Type 2 Diabetes/
NCT01243424 CAROLINA
Linagliptin
5 mg OD
6000 400 weeks
Time from randomisation to first
occurrence of CV death, non-fatal
MI, non-fatal stroke or
hospitalisation for unstable angina
pectoris
10/2010 09/2018
Petrie
Cardiovascular
D
iabetology
2013,12:130
Page
3
of
12
http://w
w
w
.cardiab.com
/content/12/1/130
Table 1 Randomised clinical trials investigating long-term cardiovascular outcomes with incretin-based therapies in people with T2D (Continued)
Cardiovascular and Renal Microvascular Outcome
Study With Linagliptin in Patients With Type 2
Diabetes Mellitus at High Vascular Risk/NCT01897532
CARMELINA
Linagliptin
5 mg OD
8300 48 months
Time to first occurrence of CV
death, non-fatal MI, non-fatal stroke
or hospitalisation for unstable
angina pectoris
07/2013 01/2018
Cardiovascular Outcomes Study of Alogliptin in
Subjects With Type 2 Diabetes and Acute Coronary
Syndrome/NCT00968708
EXAMINE
Alogliptin
25 mg OD
5380 40 months
Time from randomisation to first
occurrence of CV death, non-fatal
MI or non-fatal stroke
09/2009 Completed 06/2013
Abbreviations: CV cardiovascular, DPP-4 inhibitors, dipeptidyl peptidase-4 inhibitors, GLP-1 glucagon-like peptide-1, MI myocardial infarction, OD once daily.
All are phase 3 clinical studies, except for SAVOR- TIMI 53 and CARMELINA, phase 4 trials. All are placebo-controlled trials, except for CAROLINA (NCT01243424), in which linagliptin 5 mg OD is compared with
glimepiride 1–4 mg OD. All studies are double-blinded. Sources: www.clinicaltrials.gov; [14-24].
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experimental methods used.
Native GLP-1 exerts its effects via the GLP-1 receptor;
but may also have GLP-1 receptor-independent effects
[38]. The GLP-1 receptor is ubiquitously expressed, lo-
cated not only in pancreatic cells but also in the lungs,
kidneys, intestines, and peripheral and central nervous
systems reviewed in [26,37]. In addition, GLP-1 recep-
tors are expressed in the CV system. In mice, GLP-1 re-
ceptors are distributed in myocardial tissue (left and
right ventricles, septum and, to a lesser extent, atria),
endocardium, microvascular endothelium, and coronary
smooth muscle cells [38]. GLP-1 receptor expression in
the human heart, including the coronary artery endothe-
lial cells, has also been demonstrated [39,40].
Data from animal models and pilot clinical studies have
indicated that native GLP-1 may have cardioprotective
effects in the setting of ischaemia, or following ischaemic
injury [37,38,41,42]. For example, in a study of 21 indi-
viduals with acute MI and severe systolic dysfunction
after successful primary angioplasty, GLP-1 infusion (in
addition to standard care) significantly improved left ven-
tricular function compared with control individuals receiv-
ing standard care (including aspirin, clopidogrel, heparin,
glycoprotein IIb/IIIa inhibitors, beta-blockers, angiotensin
converting enzyme (ACE) inhibitors, and/or statins) [41].
Moreover, studies using the technique of brachial artery
flow-mediated vasodilation (measured by ultrasonography)
during GLP-1 infusion in people with T2D and stable cor-
onary artery disease suggest that GLP-1 may improve
endothelial function in some individuals with T2D [43].
The effects of GLP-1 on endothelial function have been
reviewed by Sjöholm [44].
Interestingly, in preclinical studies, cardioprotective ef-
fects were apparent in GLP-1 receptor knockout mice,
supporting the hypothesis that certain cardioprotective
actions of GLP-1 are mediated through GLP-1 receptor-
independent pathways [38].
Effects of incretin-based therapies on cardiovascular risk
factors
People with T2D who are overweight or obese, are hyper-
tensive or have dyslipidaemia are at increased risk of ad-
verse CV events. Incretin-based therapies have been shown
to have an impact on these CV risk factors; however, differ-
ences in these effects between DPP-4 inhibitors and GLP-1
receptor agonists have been noted. These differences may
arise from differences in mechanism of action, or levels of
GLP-1 receptor activation produced by these individual
drug classes [12].
Weight
Obesity increases the risk of CVD mortality in T2D [45].
As more than half of individuals with T2D are obese [46],weight control is an important aspect of CV risk manage-
ment in T2D. Encouragingly, lifestyle and certain pharma-
cological interventions that promote weight loss in people
with T2D can improve CV risk profiles [47,48].
DPP-4 inhibitors do not have major effects on weight
[12]. Sitagliptin has been associated with changes in
body weight of between 0.0 and −1.5 kg [49-52]. Clinical
studies examining saxagliptin have shown either dose-
independent, numerical decreases (−0.11 to −1.8 kg) or
increases (+0.5 to +0.8 kg) in body weight [53-56].
Meanwhile, vildagliptin treatment has been associated
with minimal weight gain of 0.2–1.3 kg [57].
In randomized controlled trials, use of the GLP-1 recep-
tor agonists exenatide, liraglutide, or lixisenatide has been
associated with body weight reductions. Exenatide BID
treatment has been associated with average weight losses
of up to 2.8 kg [58-60], and exenatide LAR with mean
weight losses of up to 3.7 kg [61-66]. Similarly, in the
GetGoal phase 3 development programme, lixisenatide
was associated with mean body weight reductions of up to
3.0 kg [67-75], although not all observed weight changes
were statistically different from comparators (placebo,
exenatide) [67,69,70,75]. In the Liraglutide Effect and Ac-
tion in Diabetes (LEAD) phase 3 clinical trials, consistent,
significant improvements in body weight were observed
with liraglutide use versus comparator arms, with average
weight losses of up to 3.2 kg [76-81].
Head-to-head trials comparing exenatide LAR [62,64]
or liraglutide [82-84] with sitagliptin have confirmed sig-
nificantly greater changes in weight with the GLP-1 re-
ceptor agonists.
Blood pressure
Hypertension is a risk factor for adverse CV events, rais-
ing the risk of coronary heart disease by approximately
2-fold and the risk of stroke by 2- to 4-fold [85,86].
Relatively few studies have examined the effects of
DPP-4 inhibitors on blood pressure in people with T2D.
Limited evidence suggests that sitagliptin may reduce
systolic blood pressure (SBP) [83,87,88], although this ef-
fect has not been observed across all studies [89]. Pooled
data from six phase 3 clinical trials indicated similar
small decreases in SBP and DBP with linagliptin 5 mg
once daily and placebo [90].
The clinically available GLP-1 receptor agonists reduce
SBP [12,25]. In phase 3, placebo-controlled studies of lixi-
senatide, reductions of up to 2.1 mmHg were observed
[25]. In the case of exenatide BID, reductions in SBP of
3.5 mmHg have been observed, with the greatest improve-
ments seen in those who lost most weight (−8.1 mmHg in
25% of subjects) [91]. Liraglutide treatment was associated
with reductions in SBP of up to 6.7 mmHg across the
LEAD phase 3 development programme [76-82]. Interest-
ingly, the reductions in SBP observed with liraglutide were
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duction does not occur solely via weight reduction [92]. As
would be predicted, meta-analysis of the liraglutide phase 3
trials showed that individuals with the highest baseline SBP
(>140 mmHg) exhibited the greatest reductions in SBP
(−11.4 mmHg) [93], and that these reductions in SBP were
independent of antihypertensive treatment [94].
Weight loss (discussed above), natriuresis and vasodila-
tion [95] are likely to contribute to the SBP-lowering ef-
fects of GLP-1 receptor agonists. A recent mouse model
study has linked GLP-1 receptor stimulation by liraglutide
to cAMP/Epac2-dependent atrial natriuretic peptide re-
lease, which would be predicted to increase natriuresis
and vasodilation, thereby lowering blood pressure [95].
Consistent with these observations, a GLP-1 receptor-
dependent, nitric oxide- and endothelium-independent
vasodilatory effect of GLP-1 has been identified in rat fem-
oral artery preparations [96].
Lipid profiles and other CV risk markers
Elevated fasting triglycerides (TG) and low density lipo-
protein cholesterol (LDL-C), and reduced high density
lipoprotein cholesterol (HDL-C), are associated with in-
creased risk of CVD [97].
DPP-4 inhibitors have been shown to have either no
effects or minor effects on fasting lipid levels in people
with T2D [90,98,99]; however, they may have an effect
on postprandial lipids. Indeed, significant reductions in
postprandial TG, apolipoprotein B-48 (ApoB-48, a LDL),
very low density lipoprotein cholesterol (VLDL-C) and
free fatty acids (FFAs) have been reported following
sitagliptin treatment [postprandial area under the curve
(AUC) reduced by 9.4, 7.8, 9.3 and 7.6%, respectively,
p < 0.05 for all measurements vs. placebo] [100]. Post-
prandial TG and ApoB-48 reductions and have also been
reported following vildagliptin treatment [incremental
AUC −2.0 ± 0.8 (p = 0.011) and −0.6 ± 0.3 (p = 0.008), re-
spectively] [101] and alogliptin treatment [incremental
AUC −3.4 ± 0.7 (p < 0.001) and −0.9 ± 0.2 (p = 0.028), re-
spectively] [102]. The effects of incretin-based therapies
on postprandial hyperlipidaemia have been reviewed
elsewhere by Ansar and colleagues [103].
While no lipid profile data have yet been published for
lixisenatide, meta-analyses have shown overall improve-
ments in fasting lipids with exenatide (BID and LAR)
and liraglutide therapy. Liraglutide reduces LDL, FFA
and TG levels (by 0.2, 0.09 and 0.2 mmol/L, respectively,
p < 0.01) and exenatide BID decreases LDL levels (by
0.15 mmol/L, p < 0.05 [104]). Trends towards reductions
in FFA and TG were also evident with exenatide, but
these did not reach statistical significance [104]. Small
decreases in HDL reported for both liraglutide and
exenatide (0.04 and 0.05 mmol/L, respectively, p < 0.01)
may not be clinically meaningful. No reductions inVLDL-C were observed for either GLP-1 receptor agon-
ist [104].
Improvements in surrogate CV risk biomarkers, such as
high sensitivity C-reactive protein (hsCRP), B-type natri-
uretic peptide (BNP), and plasminogen activator inhibitor-
1 (PAI-1) have also been observed following treatment
with liraglutide or exenatide BID [105-108].Effects of incretin-based therapies on heart rate and
cardiac repolarisation
Substantial resting heart rate elevation is associated with
increased CV mortality, and drugs that prolong cardiac
repolarisation carry a risk of provoking adverse CV
events [109,110]. What are the effects of incretin-based
therapies on these parameters?Heart rate
As resting heart rate elevation in excess of 10 beats per
minute (bpm) has been positively correlated with CV
and all-cause mortality [109], this should be evaluated
when considering the CV safety profile of a drug.
A limited amount of data regarding the effects of DPP-4
inhibitors on heart rate is available. Saxagliptin treatment
has no apparent effect on heart rate [111]. Following high
doses of linagliptin (100 mg), small increases in heart rate
(>4 bpm compared with placebo) were observed. How-
ever, no meaningful changes in heart rate were observed
in individuals who received therapeutic doses of linagliptin
(5 mg) in the same study [112].
A randomised, double-blind crossover study of intra-
venous exenatide infusion (0.12 pmol/kg/min) versus
placebo in 20 people with T2D and congestive heart fail-
ure identified acute and statistically significant increases
in placebo-corrected heart rate of 9, 14 and 15 bpm after
1, 3 and 6 hours of exenatide infusion (0.12 pmol/kg/
min), respectively [113]. However, in a separate evalu-
ation of individuals with T2D (n = 54) treated chronically
with exenatide BID for 12 weeks, heart rate was not sig-
nificantly elevated above placebo (least square mean 2.1 ±
1.4 for exenatide vs. -0.7 ± 1.4 bpm for placebo, p =
0.16 [114]). Similarly, in one study of healthy volunteers,
a transient increase in heart rate was observed with a
therapeutic dose of lixisenatide (20 μg), but no mean in-
creases in heart rate were observed with this GLP-1 re-
ceptor agonist in phase 3, placebo-controlled studies of
individuals with T2D [25]. Studies of exenatide LAR
have reported small but significant (p < 0.05) increases in
heart rate from baseline (least square mean increase of
4 ± 1 bpm [63]) and liraglutide treatment has also been
associated with increases in heart rate of 2–4 bpm
[76,77,79,81]. The mechanism behind the increase in
heart rate observed with certain GLP-1 receptor agonists
is not yet well understood. One possible explanation is
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crease in SBP.
QT interval
The electrocardiographic QT interval is a measure of
cardiac repolarisation. An increased QT interval is a risk
factor for torsades de pointes arrhythmias and sudden
cardiac death. Hence, any drug that prolongs the QT
interval may increase the risk of adverse CV events
reviewed in [110].
The DPP-4 inhibitors sitagliptin [115], saxagliptin [101]
and vildagliptin [116] are not associated with QT inter-
val prolongation at clinically relevant concentrations in
healthy individuals.
The effects of GLP-1 receptor agonists on QTc inter-
val, that is, corrected for heart rate, have been studied
in healthy volunteers. In this population, liraglutide ad-
ministration (0.6, 1.2. and 1.8 mg OD) produced no sig-
nificant QTc prolongation [117]. A significant positive
correlation between plasma exenatide concentration and
QTc interval was reported in one study following single-
dose administration of 10 μg exenatide in 62 healthy in-
dividuals [regression analysis slope (95% confidence
interval; CI), 0.02 (0.01, 0.03), p < 0.001; change in QTcF
(Fridericia correction) interval (90% prediction interval)
estimated as 4.95 (2.64, 7.25) ms at geometric mean
Cmax of exenatide] [118]. However, a further QT interval
study in which exenatide was administered by intraven-
ous infusion to achieve supratherapeutic plasma concen-
trations (up to ~630 pg/mL) was reassuring, indicating
no QTc prolongation in a population of 74 healthy adults
[119]. To date, the effects of lixisenatide on cardiac
repolarisation have not been published.
Potential cardioprotective effects of incretin-based
therapies
Consistent with the findings outlined above regarding a
cardioprotective effect of native GLP-1 under ischaemic
conditions, data from rodent and porcine models indicate
that GLP-1 receptor agonists may limit infarct size fol-
lowing ischaemia-reperfusion injury [119-122]. A possible
cardioprotective effect of exenatide following myocardial
infarction has also been identified in a clinical setting. In
people with ST-segment elevation MI undergoing primary
percutaneous coronary intervention, intravenous exena-
tide administration at the time of reperfusion led to a re-
duction in the area of myocardium at risk, as assessed by
cardiac magnetic resonance 3 months after intervention
[123]. A post hoc analysis tested the hypothesis that this ef-
fect would be more pronounced in those with short dur-
ation of ischaemia. Data from 148 participants were
stratified according to median time from ambulance call
or first contact with healthcare system to first balloon
inflation (132 min). In subjects with short durationischaemia (≤132 min), exenatide reduced final infarct size
by 30% and increased myocardial salvage index by 14%; in
contrast, no such effects were observed in those longer
duration ischaemia (>132 min) [124]. Taken together,
these findings highlight a potential cardioprotective effect
of GLP-1 receptor agonists in the setting of myocardial
ischaemia-reperfusion injury, provided they are adminis-
tered early.
Long-term effects of incretin-based therapies on
cardiovascular disease
Incretin-based therapies were amongst the first T2D treat-
ments for which detailed evaluation of long-term CV safety
was encouraged under the 2008 FDA guidance [11]. This
guidance recommends that, with regard to the risk ratio
for major adverse cardiovascular events (MACE), pre-
approval clinical trials should demonstrate that the upper
boundary of the two-sided 95% CI is less than 1.8 versus
the control group, with subsequent outcomes trials indicat-
ing a two-sided 95% CI for risk ratio of less than 1.3 [11].
MACE analyses carried out for sitagliptin [125], saxa-
gliptin [111] and alogliptin [126] have not indicated
increased CV risk. Consistent with these findings, a recent
meta-analysis identified no increased risk of CV events
with a pooled group of DPP-4 inhibitors added to
metformin versus metformin monotherapy [relative risk
(95% CI) 0.54 (0.25-1.19), p = 0.13] [127]. Indeed, DPP-4
monotherapy was associated with a significantly lower risk
of CV events than metformin monotherapy [relative risk
(95% CI) 0.36 (0.15–0.85), p = 0.0.2], indicating a possible
CV benefit of DPP-4 inhibitors [127]. Additionally, lina-
gliptin has been associated with significantly fewer CV
events than glimepiride over a 2-year period [both in com-
bination with metformin ± one additional oral antidiabetic
drug; relative risk (95% CI): 0.46 (0.23–0.91), p = 0.0213],
despite similar reductions in mean HbA1c [128].
MACE analyses conducted for GLP-1 receptor agonists
have similarly reported values within the FDA predefined
safety limits for diabetes therapies. One meta-analysis of
results from randomised trials of GLP-1 receptor agonists
(exenatide BID, exenatide LAR, liraglutide, albiglutide) for
the period up to November 2010 indicated the following
cardiovascular safety margins [Mantel-Haenszel odds ratio
for MACE (95% CI)]: all GLP-1 receptor agonists 0.74
(0.50–1.08), p = 0.12; exenatide 0.85 (0.50-1.45), p = 0.55;
liraglutide 0.69 (0.40–1.22), p = 0.20 [129]. An as-yet-
unpublished meta-analysis of eight, phase 3 studies of
lixisenatide indicated a hazard ratio (95% CI) for adjudi-
cated MACE of 1.03 (0.64, 1.66) versus placebo [25]. For
liraglutide, retrospective MACE analysis of pooled data
from all completed phase 2 and phase 3 randomised trials
to date, plus all open-label trial extensions, indicated
that the incidence ratio for broad/serious adjudicated
MACE versus comparator drugs (metformin, glimepiride,
Petrie Cardiovascular Diabetology 2013, 12:130 Page 8 of 12
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CI 0.38, 1.41) [130].
These pooled data, mostly from phase 2 and 3 trials, are
complemented by reassuring observational data. For ex-
ample, a retrospective analysis of the U.S. LifeLink™ data-
base of medical and pharmaceutical insurance claims (for
the period June 2005 to March 2009) indicated that
exenatide BID was not associated with an excess CV risk
compared to other glucose-lowering therapies [131]. Con-
sistent with this, another retrospective analysis found no
elevated risk of MACE with exenatide BID compared to
insulin for ≤1 year [132].
The long-term CV safety and efficacy of many incretin-
based therapies are being prospectively evaluated in
randomised control trials (Table 1). With the exception of
the EXSCEL study, all include people with pre-existing
CV disease and/or people with high risk for CV disease
[16-24]. As of September 2013, a body of evidence is be-
ginning to emerge on the long-term CV safety profile of
incretin-based therapies in individuals at high risk of CV
events: the results of the first two trials (SAVOR-TIMI 53
[saxagliptin] [22] and EXAMINE (alogliptin [24]), pub-
lished as this article went to press, meet the FDA criteria
for non-inferiority of these agents over placebo but
provide no positive evidence of CV risk reduction. More
evidence is eagerly awaited to inform clinical decision-
making when seeking to minimise the risk of CVD in
people with T2D.
Conclusions
In addition to their glucose-lowering properties, incretin-
based therapies have apparently beneficial effects on CV
risk factors, accompanied by small effects on heart rate,
without clinically meaningful QTc prolongation. There is
mechanistic evidence to suggest that GLP-1 receptor ago-
nists may confer cardioprotective effects following ischae-
mia. Retrospective MACE analyses conducted for the
different incretin based therapies have been reassuring.
However, as mandated by regulatory agencies, the long-
term CV safety of DPP-4 inhibitors and GLP-1 receptor
agonists is currently under investigation in large CV out-
comes trials. The results – which will emerge over the
next few years – may also provide data on the efficacy of
incretin-based agents in preventing CV events. This infor-
mation will supply the evidence needed to position the use
of these classes rationally amongst other more established
glucose-lowering therapies.
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